Stanley Zhou· @stanleytor · X·· 2 天前评分70
正文 · 原文
LITESPARK-012 data showing adding belzutifan or anti-CTLA to pembro / lenvatinib does not really improve outcome may be one of my favorites from ESMO.
Negative data is just as important.
#ESMO2026
5 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Stanley Zhou · x.com